DHPLC screening of cystic fibrosis gene mutations

Denaturing high performance liquid chromatography (DHPLC) using ion‐pairing reverse phase chromatography (IPRPC) columns is a technique for the screening of gene mutations. In order to evaluate the potential utility of this assay method in a clinical laboratory setting, we subjected the PCR products of 73 CF patients known to bear CFTR mutations to this analytic technique. We used thermal denaturation profile parameters specified by the MELT program tool, made available by Stanford University. Using this strategy, we determined an initial analytic sensitivity of 90.4% for any of 73 known CFTR mutations. Most of the mutations not detected by DHPLC under these conditions are α‐substitutions. This information may eventually help to improve the MELT algorithm. Increasing column denaturation temperatures for one or two degrees above those recommended by the MELT program allowed 100% detection of CFTR mutations tested. By comparing DHPLC methodology used in this study with the recently reported study based on Wavemaker 3.4.4 software (Transgenomic, Omaha, NE) [Le Marechal et al., 2001) and with previous SSCP analysis of CFTR mutations [Ravnik‐Glavač et al., 1994] we emphasized differences and similarities in order to refine the DHPLC system and discuss the relationship to the alternative approaches. We conclude that the DHPLC method, under optimized conditions, is highly accurate, rapid, and efficient in detecting mutations in the CFTR gene and may find high utility in screening individuals for CFTR mutations. Hum Mutat 19:374–383, 2002. Published 2002 Wiley‐Liss, Inc.

[1]  P. Oefner,et al.  Denaturing high‐performance liquid chromatography: A review , 2001, Human mutation.

[2]  C. Férec,et al.  Complete and rapid scanning of the cystic fibrosis transmembrane conductance regulator (CFTR) gene by denaturing high-performance liquid chromatography (D-HPLC): major implications for genetic counselling , 2001, Human Genetics.

[3]  B. Zbar,et al.  Random mutagenesis‐PCR to introduce alterations into defined DNA sequences for validation of SNP and mutation detection methods , 2001, Human mutation.

[4]  K. Klinger,et al.  Laboratory standards and guidelines for population-based cystic fibrosis carrier screening , 2001, Genetics in Medicine.

[5]  W. Grody,et al.  Cystic fibrosis population carrier screening: Here at last—Are we ready? , 2001, Genetics in Medicine.

[6]  R. Cotton,et al.  Using CCM and DHPLC to detect mutations in the glucocorticoid receptor in atherosclerosis: a comparison. , 2001, Journal of biochemical and biophysical methods.

[7]  H. Zoghbi,et al.  Diagnostic testing for Rett syndrome by DHPLC and direct sequencing analysis of the MECP2 gene: identification of several novel mutations and polymorphisms. , 2000, American journal of human genetics.

[8]  H. Smeets,et al.  Autosomal dominant Alport syndrome caused by a COL4A3 splice site mutation. , 2000, Kidney international.

[9]  X. Estivill,et al.  Recommendations for quality improvement in genetic testing for cystic fibrosis European Concerted Action on Cystic Fibrosis , 2000, European Journal of Human Genetics.

[10]  E. Lau,et al.  Prenatal diagnosis of glycogen storage disease type 1b using denaturing high performance liquid chromatography , 2000, Prenatal diagnosis.

[11]  R. Santer,et al.  Molecular analysis in glycogen storage disease 1 non‐A: DHPLC detection of the highly prevalent exon 8 mutations of the G6PT1 gene in German patients , 2000, Human mutation.

[12]  C. Giunta,et al.  Characterization of 11 new mutations in COL3A1 of individuals with Ehlers‐Danlos syndrome type IV: Preliminary comparison of RNase cleavage, EMC and DHPLC assays , 2000, Human mutation.

[13]  J. Cheadle,et al.  Application and evaluation of denaturing HPLC for molecular genetic analysis in tuberous sclerosis , 2000, Human Genetics.

[14]  D. Kwiatkowski,et al.  Superiority of Denaturing High Performance Liquid Chromatography over single‐stranded conformation and conformation‐sensitive gel electrophoresis for mutation detection in TSC2 , 1999, Annals of human genetics.

[15]  M. O’Donovan,et al.  Optimal temperature selection for mutation detection by denaturing HPLC and comparison to single-stranded conformation polymorphism and heteroduplex analysis. , 1999, Clinical chemistry.

[16]  E. Gross,et al.  A comparison of BRCA1 mutation analysis by direct sequencing, SSCP and DHPLC , 1999, Human Genetics.

[17]  M. Mennuti,et al.  Screening for cystic fibrosis carrier state. , 1999, Obstetrics and gynecology.

[18]  S N Thibodeau,et al.  Denaturing high performance liquid chromatography (DHPLC) used in the detection of germline and somatic mutations. , 1998, Nucleic acids research.

[19]  M. Ferrari,et al.  Optimized Detection of DNA Point Mutations by Double Gradient Denaturing Gradient Gel , 1998, Clinical chemistry and laboratory medicine.

[20]  R. W. Davis,et al.  Detection of numerous Y chromosome biallelic polymorphisms by denaturing high-performance liquid chromatography. , 1997, Genome research.

[21]  A. Macková,et al.  Identification of common cystic fibrosis mutations in African-Americans with cystic fibrosis increases the detection rate to 75%. , 1997, American journal of human genetics.

[22]  Xavier Estivill,et al.  Complexity in a monogenic disease , 1996, Nature Genetics.

[23]  D. Glavač,et al.  Sensitivity of single-strand conformation polymorphism and heteroduplex method for mutation detection in the cystic fibrosis gene. , 1994, Human molecular genetics.

[24]  X. Estivill,et al.  Analysis of the CFTR gene confirms the high genetic heterogeneity of the Spanish population: 43 mutations account for only 78% of CF chromosomes , 1994, Human Genetics.

[25]  A. Ferguson,et al.  Three novel mutations in the cystic fibrosis gene detected by chemical cleavage: analysis of variant splicing and a nonsense mutation. , 1992, Human molecular genetics.

[26]  L. Tsui,et al.  Genomic DNA sequence of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. , 1991, Genomics.

[27]  L. Tsui,et al.  The cystic fibrosis gene: isolation and significance. , 1990, Hospital practice.

[28]  E. L. Pettit,et al.  Novel method for molecular detection of the two common hereditary hemochromatosis mutations. , 2000, Genetic testing.

[29]  J. Wahlström,et al.  Denaturing high-performance liquid chromatography is a suitable method for PMM2 mutation screening in carbohydrate-deficient glycoprotein syndrome type IA patients. , 2000, Genetic Testing.

[30]  D. Glavač,et al.  Screening methods for cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in non-human primates , 2000, Pflügers Archiv.

[31]  D. Glavač,et al.  Screening methods for cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in non-human primates , 2000, Pflügers Archiv: European Journal of Physiology.

[32]  Genetic testing for cystic fibrosis. National Institutes of Health Consensus Development Conference Statement on genetic testing for cystic fibrosis. , 1999, Archives of internal medicine.

[33]  X. Estivill,et al.  Geographic distribution and regional origin of 272 cystic fibrosis mutations in European populations , 1997 .

[34]  X. Estivill,et al.  Geographic distribution and regional origin of 272 cystic fibrosis mutations in European populations. The Biomed CF Mutation Analysis Consortium. , 1997, Human mutation.

[35]  L. Tsui,et al.  Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. , 1989, Science.